MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Aug. 7, 2006--MedaSorb Technologies, a medical device company engaged in the development and commercialization of CytoSorb and BetaSorb for removing toxic compounds from the blood, today announced its stock will begin to trade under the symbol OTC BB: MSBT on August 8, 2006. MedaSorb completed the reverse merger transaction on June 30, 2006 and immediately closed a $5.25 million private placement of its Series A 10% Cumulative Convertible Preferred Stock and Warrants to purchase Common Stock.
